Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round
⇨ A Cambridge, MA-based startup named 2X Oncology has in-licensed a mid-stage PARP inhibitor from Eisai. A spin-out of Oncology Venture, their web site …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
